Locations:
Research program sets the stage for clinical trials
Researchers use AI tools to compare clinical events with continuous patient monitoring
Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Findings strengthen evidence for risk-reducing procedures
Findings from large database important to inform clinical practice
Offers a new option for patients 60 and older with relapsed/refractory disease
Researchers develop first-of-its-kind neoantigen atlas to better understand immunotherapy resistance
Advertisement
Advertisement
Search